Paula T. Einhorn

2.7k total citations
37 papers, 1.2k citations indexed

About

Paula T. Einhorn is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism and Surgery. According to data from OpenAlex, Paula T. Einhorn has authored 37 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Cardiology and Cardiovascular Medicine, 10 papers in Endocrinology, Diabetes and Metabolism and 7 papers in Surgery. Recurrent topics in Paula T. Einhorn's work include Blood Pressure and Hypertension Studies (28 papers), Health Systems, Economic Evaluations, Quality of Life (7 papers) and Hormonal Regulation and Hypertension (6 papers). Paula T. Einhorn is often cited by papers focused on Blood Pressure and Hypertension Studies (28 papers), Health Systems, Economic Evaluations, Quality of Life (7 papers) and Hormonal Regulation and Hypertension (6 papers). Paula T. Einhorn collaborates with scholars based in United States, Canada and Australia. Paula T. Einhorn's co-authors include Barry R. Davis, William C. Cushman, Charles E. Ford, Lara M. Simpson, Paul K. Whelton, Barry M. Massie, Suzanne Oparil, Gail T. Louis, Jackson T. Wright and L. Julian Haywood and has published in prestigious journals such as Circulation, SHILAP Revista de lepidopterología and Annals of Internal Medicine.

In The Last Decade

Paula T. Einhorn

37 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Paula T. Einhorn United States	17	910	311	161	110	94	37	1.2k
Yuan‐Yuan Kang China	13	926 1.0×	392 1.3×	238 1.5×	163 1.5×	114 1.2×	48	1.4k
Marcelo C. Shibata Canada	13	1.7k 1.9×	256 0.8×	168 1.0×	151 1.4×	134 1.4×	20	2.1k
Carlos Escobar Spain	22	1.4k 1.6×	404 1.3×	279 1.7×	158 1.4×	64 0.7×	199	2.0k
Andrea Ferrucci Italy	17	671 0.7×	189 0.6×	130 0.8×	115 1.0×	72 0.8×	63	916
Gina D. Schellenbaum United States	7	652 0.7×	239 0.8×	128 0.8×	98 0.9×	87 0.9×	7	997
Mathieu Ghadanfar United States	16	769 0.8×	228 0.7×	94 0.6×	58 0.5×	60 0.6×	27	1.0k
Lara M. Simpson United States	16	896 1.0×	273 0.9×	372 2.3×	88 0.8×	175 1.9×	36	1.3k
Annette Champion United States	14	1.4k 1.5×	321 1.0×	239 1.5×	175 1.6×	91 1.0×	23	1.7k
Emily Atkins Australia	16	804 0.9×	224 0.7×	216 1.3×	155 1.4×	99 1.1×	69	1.4k
Juan García‐Puig Spain	17	550 0.6×	307 1.0×	140 0.9×	94 0.9×	87 0.9×	45	1.0k

Countries citing papers authored by Paula T. Einhorn

Since Specialization

Citations

This map shows the geographic impact of Paula T. Einhorn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paula T. Einhorn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paula T. Einhorn more than expected).

Fields of papers citing papers by Paula T. Einhorn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paula T. Einhorn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paula T. Einhorn. The network helps show where Paula T. Einhorn may publish in the future.

Co-authorship network of co-authors of Paula T. Einhorn

This figure shows the co-authorship network connecting the top 25 collaborators of Paula T. Einhorn. A scholar is included among the top collaborators of Paula T. Einhorn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paula T. Einhorn. Paula T. Einhorn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Keteyian, Steven J., Joseph Finkelstein, Daniel E. Forman, et al.. (2023). Baseline Characteristics and Barriers to Recruitment in Cardiac and Pulmonary Rehabilitation NIH-Funded Trials. Journal of Cardiopulmonary Rehabilitation and Prevention. 43(6). 407–411. 2 indexed citations

Bowling, C. Barrett, Richard Sloane, Carl F. Pieper, et al.. (2021). Association of Sustained Blood Pressure Control with Lower Risk for High-Cost Multimorbidities Among Medicare Beneficiaries in ALLHAT. Journal of General Internal Medicine. 36(8). 2221–2229. 2 indexed citations

Muntner, Paul, Jeff Whittle, Amy I. Lynch, et al.. (2020). Visit-to-Visit Variability of Blood Pressure and Coronary Heart Disease, Stroke, Heart Failure, and Mortality. Annals of Internal Medicine. 3 indexed citations

Barzilay, Joshua I., Barry R. Davis, Sara Pressel, et al.. (2018). The Effects of eGFR Change on CVD, Renal, and Mortality Outcomes in a Hypertensive Cohort Treated With 3 Different Antihypertensive Medications. American Journal of Hypertension. 31(5). 609–614. 13 indexed citations

Barzilay, Joshua I., Barry R. Davis, Alokananda Ghosh, et al.. (2018). Rapid eGFR change as a determinant of cardiovascular and renal disease outcomes and of mortality in hypertensive adults with and without type 2 diabetes. Journal of Diabetes and its Complications. 32(9). 830–832. 8 indexed citations

Davis, Barry R., Sara Pressel, Paul K. Whelton, et al.. (2016). Association of 3 Different Antihypertensive Medications With Hip and Pelvic Fracture Risk in Older Adults. JAMA Internal Medicine. 177(1). 67–67. 45 indexed citations

Ernst, Michael E., Barry R. Davis, Elsayed Z. Soliman, et al.. (2016). Electrocardiographic measures of left ventricular hypertrophy in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Journal of the American Society of Hypertension. 10(12). 930–938.e9. 8 indexed citations

Pavlik, Valory, David J. Hyman, Penny H. Feldman, et al.. (2015). Designing and Evaluating Health Systems Level Hypertension Control Interventions for African-Americans: Lessons from a Pooled Analysis of Three Cluster Randomized Trials. Current Hypertension Reviews. 11(2). 123–131. 12 indexed citations

Alderman, Michael H., Barry R. Davis, Linda B. Piller, et al.. (2015). Should Antihypertensive Treatment Recommendations Differ in Patients With and Without Coronary Heart Disease? (from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial [ALLHAT]). The American Journal of Cardiology. 117(1). 105–115. 6 indexed citations

10.

Shah, Ravi V., Siddique Abbasi, José‐Miguel Yamal, et al.. (2014). Impaired Fasting Glucose and Body Mass Index as Determinants of Mortality in ALLHAT: Is the Obesity Paradox Real?. Journal of Clinical Hypertension. 16(6). 451–458. 19 indexed citations

11.

Piller, Linda B., Jeff D. Williamson, Jeff Whittle, et al.. (2013). Risk of Hospitalized Gastrointestinal Bleeding in Persons Randomized to Diuretic, ACE‐Inhibitor, or Calcium‐Channel Blocker in ALLHAT. Journal of Clinical Hypertension. 15(11). 825–832. 8 indexed citations

12.

Margolis, Karen L., Barry R. Davis, Jerry O. Ciocon, et al.. (2013). Long‐Term Follow‐Up of Moderately Hypercholesterolemic Hypertensive Patients Following Randomization to Pravastatin vs Usual Care: The Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT‐LLT). Journal of Clinical Hypertension. 15(8). 542–554. 20 indexed citations

13.

Barzilay, Joshua I., Barry R. Davis, Sara Pressel, et al.. (2012). Long-Term Effects of Incident Diabetes Mellitus on Cardiovascular Outcomes in People Treated for Hypertension. Circulation Cardiovascular Quality and Outcomes. 5(2). 153–162. 48 indexed citations

14.

Alderman, Michael H., Linda B. Piller, Charles E. Ford, et al.. (2012). Clinical Significance of Incident Hypokalemia and Hyperkalemia in Treated Hypertensive Patients in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Hypertension. 59(5). 926–933. 51 indexed citations

15.

Margolis, Karen L., Kay Dunn, Lara M. Simpson, et al.. (2009). Coronary heart disease in moderately hypercholesterolemic, hypertensive black and non-black patients randomized to pravastatin versus usual care: The Antihypertensive and Lipid Lowering to Prevent Heart Attack Trial (ALLHAT-LLT). American Heart Journal. 158(6). 948–955. 13 indexed citations

16.

Haywood, L. Julian, Charles E. Ford, Richard S. Crow, et al.. (2009). Atrial Fibrillation at Baseline and During Follow-Up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). Journal of the American College of Cardiology. 54(22). 2023–2031. 133 indexed citations

17.

Bartholomew, L. Kay, William C. Cushman, Jeffrey A. Cutler, et al.. (2009). Getting clinical trial results into practice: design, implementation, and process evaluation of the ALLHAT Dissemination Project. Clinical Trials. 6(4). 329–343. 15 indexed citations

18.

Cushman, William C., Charles E. Ford, Paula T. Einhorn, et al.. (2008). Blood Pressure Control by Drug Group in the Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Journal of Clinical Hypertension. 10(10). 751–760. 70 indexed citations

19.

Einhorn, Paula T., Barry R. Davis, Barry M. Massie, et al.. (2006). The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) heart failure Validation Study: Diagnosis and prognosis. American Heart Journal. 153(1). 42–53. 45 indexed citations

20.

Piller, Linda B., Barry R. Davis, Jeffrey A. Cutler, et al.. (2002). Validation of Heart Failure Events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants Assigned to Doxazosin and Chlorthalidone. SHILAP Revista de lepidopterología. 3(1). 10–10. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact